Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
In hypophosphatasia (HPP), DEXA T-scores can read normal or even high because the scan measures mineral quantity, not the defective mineralization, softened osteomalacic bone, and impaired healing that actually drive fractures such as metatarsal stress fractures and atypical femoral fractures. T-scores are also the wrong yardstick for children and young adults, where Z-scores apply, and standard risk tools were never validated in a rare metabolic bone disease, so low alkaline phosphatase, elevated vitamin B6, dental history, and pain patterns often reveal more than density numbers do. Misreading a T-score can lead to treatments like bisphosphonates that may worsen HPP, making the details of interpretation critical; several factors are involved, so see below to understand more.
If you are dealing with unexplained fractures, bone pain, muscle weakness, or lab results that do not match how you feel, the fastest way to organize your concerns before your next appointment is a free, instant symptom check that walks you through your specific pattern of symptoms in minutes. It will not replace your specialist, but it can help you frame the right questions, flag findings worth investigating, and take a clearer next step instead of waiting and wondering.
Last reviewed for medical accuracy: 08/18/2026
Bone density testing with DEXA (dual-energy X-ray absorptiometry) is a cornerstone for assessing osteoporosis and fracture risk in the general population. However, in adults living with hypophosphatasia (HPP), standard DEXA T-scores often miss the mark. Understanding why can help you advocate for more accurate assessments and tailored care.
Hypophosphatasia is a rare, inherited metabolic bone disorder caused by mutations in the ALPL gene. The resulting deficiency of alkaline phosphatase leads to:
In adults, you might encounter references to your “Hypophosphatasia adult bone density T score.” While this metric can offer a snapshot of mineral content, it doesn’t capture the full picture of bone quality in HPP.
A DEXA scan reports:
For most people:
But in HPP, these thresholds may be misleading.
Bone Quality vs. Bone Quantity
Reference Database Limitations
Variations in Bone Compartments
Undetected Pseudofractures and Stress Reactions
Calcification of Soft Tissues and Joints
Misleading Fracture Risk Calculators
Because DEXA T-scores alone may understate fracture risk in HPP, consider discussing these additional assessments with your doctor:
High-Resolution Peripheral Quantitative CT (HR-pQCT)
Provides a 3D view of trabecular microarchitecture and cortical porosity.
Bone Turnover Markers
Blood or urine tests (e.g., osteocalcin, C-telopeptide) can reveal abnormal bone formation or resorption rates.
Vertebral Morphometry
Lateral spine X-rays detect lost height in vertebral bodies—early signs of compression fractures.
Targeted Radiographs
Imaging of areas prone to pseudofractures (femur, metatarsals) can catch stress reactions before they become complete breaks.
Bone Biopsy (in Select Cases)
Though invasive, a biopsy can directly show mineralization defects and tissue quality.
When you review a DEXA report, keep these points in mind:
Living with HPP means staying vigilant about bone health and possible complications. If you experience:
…consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you prioritize concerns before your next medical appointment.
Because standard bone density measurements may not fully capture your risk, it’s crucial to:
It’s normal to feel concerned when standard tests don’t tell the whole story. Yet:
If you have symptoms that concern you or if your fracture risk feels uncertain, speak to a doctor. For non-urgent questions, you might also use the doctor-approved Ubie Symptom Checker for a free, online symptom checkup. And never hesitate to get immediate medical attention if you suspect a serious fracture or life-threatening complication.
(References)
* Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Dahir KM, Nunes ME. Hypophosphatasia. GeneReviews(®). 1993. PMID: 20301329.
* Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Lewiecki EM. Osteoporosis: Clinical Evaluation. Endotext. 2000. PMID: 25905277.
* Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Marini JC, Dang Do AN. Osteogenesis Imperfecta. Endotext. 2000. PMID: 25905334.
* Uebelhart B, Rizzoli R. [Bone diseases]. Rev Med Suisse. 2016 Jan 13;12(500):49-54. PMID: 26946704.
* Kishnani PS, Rockman-Greenberg C, Rauch F, Bhatti MT, Moseley S, Denker AE, Watsky E, Whyte MP. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019 Apr;121:149-162. doi: 10.1016/j.bone.2018.12.011. Epub 2018 Dec 18. PMID: 30576866.
* Jannin A, Kerlan V, Desailloud R. Endocrinology of bone mineralization: An update. Ann Endocrinol (Paris). 2022 Feb;83(1):46-53. doi: 10.1016/j.ando.2021.12.001. Epub 2021 Dec 16. PMID: 34921812.
* Tobias JH, Brunetti G. Editorial: Insights in bone research 2021. Front Endocrinol (Lausanne). 2022;13:979276. doi: 10.3389/fendo.2022.979276. Epub 2022 Jul 26. PMID: 35957823; PMCID: PMC9362978.
* Rush E, Brandi ML, Khan A, Ali DS, Al-Alwani H, Almonaei K, Alsarraf F, Bacrot S, Dahir KM, Dandurand K, Deal C, Ferrari SL, Giusti F, Guyatt G, Hatcher E, Ing SW, Javaid MK, Khan S, Kocijan R, Lewiecki EM, Linglart A, M'Hiri I, Marini F, Nunes ME, Rockman-Greenberg C, Roux C, Seefried L, Starling SR, Ward L, Yao L, Brignardello-Petersen R, Simmons JH. Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working Group. Osteoporos Int. 2024 Jan;35(1):1-10. doi: 10.1007/s00198-023-06843-2. Epub 2023 Nov 20. PMID: 37982855; PMCID: PMC10786745.
* Wade E, Mulholland K, Shaw I, Cundy T, Robertson S. Idiopathic juvenile osteoporosis-a polygenic disorder? JBMR Plus. 2024 Sep;8(9):ziae099. doi: 10.1093/jbmrpl/ziae099. Epub 2024 Jul 29. PMID: 39193113; PMCID: PMC11347881.
* Gill AS, Sharma P, Nassar M, Marte E. Hypophosphatasia: A case report. World J Clin Cases. 2025 Jul 26;13(21):103642. doi: 10.12998/wjcc.v13.i21.103642. PMID: 40726933; PMCID: PMC12068182.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.